Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006025 · ClinicalTrials.gov registry record · Phase 1
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006025 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00006025, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
Interventions
- DRUG temozolomide
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01-05 |
| Est. Completion | 2007-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006025
The ClinicalTrials.gov registry entry for NCT00006025 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00006025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006025 about?
NCT00006025 is a clinical study titled "Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurren...
What is the current status of trial NCT00006025?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-01-05. Estimated completion is 2007-12-01.
What interventions are being tested in trial NCT00006025?
The interventions under investigation include: temozolomide (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006025?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.